News for Mirum Pharmaceuticals, Inc. (MIRM.MX)

Mirum Pharmaceuticals receives FDA approval for a new tablet form of its liver disease medication, Livmarli. Analysts project an average price target of

Summary Mirum Pharmaceuticals Inc (MIRM) announced on April 10, 2025, that its Compensation Committee has granted inducement awards to seven new employees. Thes

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement

Discover why Mirum Pharmaceuticals, Inc. stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click for my MIRM update.

On March 10, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant stock transaction involving Acelyrin Inc. The firm added 1,526,365 sha

Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (N

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement

Strengths: Innovative rare disease therapies and robust pipeline with potential for market expansion.Weaknesses: Ongoing net losses and reliance on third-party

On February 25, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant transaction by acquiring an additional 2,000,000 shares of Acelyrin

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ETCompany ParticipantsAndrew McKibben - Senior Vice...

Total Net Product Sales (Q4 2024): $99.4 million, a 43% year-over-year increase from $69.5 million in Q4 2023.Total Net Product Sales (Full Year 2024): $336.4

Feb 26, 2025 / 09:30PM GMTOperator Hello, and welcome to Mirum Pharmaceuticals reports fourth quarter and year-end 2024 financial results and provides business

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -81.48% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals Inc (MIRM) announced its financial results for the fourth quarter and full year of 2024, alongside a business update. The company reported

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. ”œ2024

On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.

Mirum Pharmaceuticals Inc (MIRM) announced on [date of press release] that the U.S. Food and Drug Administration (FDA) has approved CTEXLIâ„¢ (chenodiol) tablet

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLIâ„¢ (chenodiol) tablets, a bile

On February 18, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 5,298,328 shares of Acelyrin Inc. This acqu